A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are three cash-producing companies to steer clear of and a few better alternatives.
Integer Holdings (ITGR)
Trailing 12-Month Free Cash Flow Margin: 6.1%
With its name reflecting the mathematical term for "whole" or "complete," Integer Holdings (NYSE: ITGR) is a medical device outsource manufacturer that produces components and systems for cardiac, vascular, neurological, and other medical applications.
Why Does ITGR Worry Us?
- Sales trends were unexciting over the last two years as its 6.1% annual growth was below the typical healthcare company
- Revenue base of $1.84 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Estimated sales growth of 1.5% for the next 12 months implies demand will slow from its two-year trend
Integer Holdings is trading at $126.34 per share, or 18.9x forward P/E. Dive into our free research report to see why there are better opportunities than ITGR.
DaVita (DVA)
Trailing 12-Month Free Cash Flow Margin: 11.5%
With over 2,600 dialysis centers across the United States and a presence in 13 countries, DaVita (NYSE: DVA) operates a network of dialysis centers providing treatment and care for patients with chronic kidney disease and end-stage kidney disease.
Why Is DVA Not Exciting?
- Flat treatments over the past two years imply it may need to invest in improvements to get back on track
- Estimated sales growth of 2% for the next 12 months implies demand will slow from its two-year trend
- Adjusted operating margin failed to increase over the last two years, indicating the company couldn’t optimize its expenses
DaVita’s stock price of $176.97 implies a valuation ratio of 11.4x forward P/E. Read our free research report to see why you should think twice about including DVA in your portfolio.
Merck (MRK)
Trailing 12-Month Free Cash Flow Margin: 24.1%
With roots dating back to 1891 and a portfolio that includes the blockbuster cancer immunotherapy Keytruda, Merck (NYSE: MRK) develops and sells prescription medicines, vaccines, and animal health products across oncology, infectious diseases, cardiovascular, and other therapeutic areas.
Why Do We Think Twice About MRK?
- Weak constant currency growth over the past two years indicates challenges in maintaining its market share
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 19.9 percentage points
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 11.1% annually while its revenue grew
At $150.00 per share, Merck trades at 17.4x forward P/E. To fully understand why you should be careful with MRK, check out our full research report (it’s free).
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
